Analyte Specific Reagents for Cystic Fibrosis

New analyte specific reagents (ASRs) are designed to detect the 25 gene mutations most commonly associated with cystic fibrosis (CF).

CF is one of the most common genetic disorders in Caucasian populations of European descent, carried in about one in 29 Caucasians. May medical experts recommend that all women contemplating pregnancy should be offered a screen of the CF gene, CFTR, by their doctors. The CF ASRs may be used by laboratories to screen and genotype individuals for mutations in the CFTR gene. The assays can be performed on the NanoChip Molecular Biology Workstation of Nanogen, Inc. (San Diego, CA, USA), which developed the reagents. Nanogen says this is the first microarray capable of performing such an analysis of the CFTR gene

"In less then nine months, we have delivered on our promise to design what is thought to be one of the most complex genetic assays being performed today into highly accurate, cost-effective and simple-to-use ASRs,” said Dr. Randy White, CEO of Nanogen. "We believe we are well positioned to enter the CF testing market with the NanoChip System due to several competitive factors favoring its adoption.”




Related Links:
Nanogen